Search

Your search keyword '"Maximilian Töllner"' showing total 5 results
Start Over Author "Maximilian Töllner" Topic variants of concern
5 results on '"Maximilian Töllner"'

1. Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid

Author

Louise Benning, Christian Morath, Tessa Kühn, Marie Bartenschlager, Heeyoung Kim, Jörg Beimler, Mirabel Buylaert, Christian Nusshag, Florian Kälble, Marvin Reineke, Maximilian Töllner, Matthias Schaier, Katrin Klein, Antje Blank, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Thuong Hien Tran, and Claudius Speer

Subjects
SARS-CoV-2, kidney transplantation, variants of concern, delta variant, omicron variant, SARS-CoV-2 vaccination, Medicine (General), R5-920
Abstract

Seroconversion rates after COVID-19 vaccination are significantly lower in kidney transplant recipients compared to healthy cohorts. Adaptive immunization strategies are needed to protect these patients from COVID-19. In this prospective observational cohort study, we enrolled 76 kidney transplant recipients with no seroresponse after at least three COVID-19 vaccinations to receive an additional mRNA-1273 vaccination (full dose, 100 μg). Mycophenolic acid was withdrawn in 43 selected patients 5–7 days prior to vaccination and remained paused for 4 additional weeks after vaccination. SARS-CoV-2-specific antibodies and neutralization of the delta and omicron variants were determined using a live-virus assay 4 weeks after vaccination. In patients with temporary mycophenolic acid withdrawal, donor-specific anti-HLA antibodies and donor-derived cell-free DNA were monitored before withdrawal and at follow-up. SARS-CoV-2 specific antibodies significantly increased in kidney transplant recipients after additional COVID-19 vaccination. The effect was most pronounced in individuals in whom mycophenolic acid was withdrawn during vaccination. Higher SARS-CoV-2 specific antibody titers were associated with better neutralization of SARS-CoV-2 delta and omicron variants. In patients with short-term withdrawal of mycophenolic acid, graft function and donor-derived cell-free DNA remained stable. No acute rejection episode occurred during short-term follow-up. However, resurgence of prior anti-HLA donor-specific antibodies was detected in 7 patients.

Published
2022
Full Text
View/download PDF

2. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

Author

Louise Benning, Katrin Klein, Christian Morath, Marie Bartenschlager, Heeyoung Kim, Mirabel Buylaert, Marvin Reineke, Maximilian Töllner, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Matthias Schaier, and Claudius Speer

Subjects
SARS-CoV-2, COVID-19, hemodialysis, variants of concern, delta variant, Immunologic diseases. Allergy, RC581-607
Abstract

Hemodialysis patients are at high risk for severe COVID-19, and impaired seroconversion rates have been demonstrated after COVID-19 vaccination. Humoral immunity wanes over time and variants of concern with immune escape are posing an increasing threat. Little is known about protection against the B.1.617.2 (delta) variant of concern in hemodialysis patients before and after third vaccination. We determined anti-S1 IgG, surrogate neutralizing, and IgG antibodies against different SARS-CoV-2 epitopes in 84 hemodialysis patients directly before and three weeks after a third vaccine dose with BNT162b2. Third vaccination was performed after a median (IQR) of 119 (109–165) days after second vaccination. In addition, neutralizing activity against the B.1.617.2 (delta) variant was assessed in 31 seroconverted hemodialysis patients before and after third vaccination. Triple seropositivity for anti-S1 IgG, surrogate neutralizing, and anti-RBD antibodies increased from 31/84 (37%) dialysis patients after second to 80/84 (95%) after third vaccination. Neutralizing activity against the B.1.617.2 (delta) variant was significantly higher after third vaccination with a median (IQR) ID50 of 1:320 (1:160–1:1280) compared with 1:20 (0–1:40) before a third vaccine dose (P

Published
2022
Full Text
View/download PDF

3. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination

Author

Louise Benning, Christian Morath, Marie Bartenschlager, Christian Nusshag, Florian Kälble, Mirabel Buylaert, Matthias Schaier, Jörg Beimler, Katrin Klein, Julia Grenz, Paula Reichel, Asa Hidmark, Gerald Ponath, Maximilian Töllner, Marvin Reineke, Susanne Rieger, Burkhard Tönshoff, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Claudius Speer, Süsal, Caner (ORCID 0000-0003-2521-8201 & YÖK ID 351800), Benning, Louise, Morath, Christian, Bartenschlager, Marie, Nusshag, Christian, Kalble, Florian, Buylaert, Mirabel, Schaier, Matthias, Beimler, Jorg, Klein, Katrin, Grenz, Julia, Reichel, Paula, Hidmark, Asa, Ponath, Gerald, Tollner, Maximilian, Reineke, Marvin, Rieger, Susanne, Tonshoff, Burkhard, Schnitzler, Paul, Zeier, Martin, Bartenschlager, Ralf, Speer, Claudius, and School of Medicine

Subjects
Adult, Male, Transplantation, COVID-19, SARS-CoV-2, Kidney transplantation, Variants of concern, Vaccination, COVID-19 Vaccines, Epidemiology, Middle Aged, Critical Care and Intensive Care Medicine, Kidney Transplantation, Urology and nephrology, Editorial, Nephrology, Humans, Female, Prospective Studies
Abstract

Background and objectives: antibody response after severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) vaccination is impaired in kidney transplant recipients. Emerging variants, such as B.1.617.2 ( d), are of particular concern because of their higher transmissibility and partial immune escape. Little is known about protection against these variants in immunocompromised patients. Design, setting, participants, and measurements: in this prospective two-center study, antispike 1 IgG and surrogate neutralizing antibodies were measured in 173 kidney transplant recipients and 166 healthy controls with different vaccination schedules. In addition, different SARS-CoV-2 epitope antibodies from 135 vaccinated kidney transplant recipients were compared with antibodies in 25 matched healthy controls after second vaccination. In 36 kidney transplant recipients with seroconversion, neutralization against B.1.1.7 ( a), B.1.351 ( b), and B.1.617.2 ( d) was determined on VeroE6 cells and compared with neutralization in 25 healthy controls. Results: kidney transplant recipients had significantly lower seroconversion rates compared with healthy controls. After the second vaccination, antispike 1, antireceptor-binding domain, and surrogate neutralizing antibodies were detectable in 30%, 27%, and 24% of kidney transplant recipients, respectively. This compares with 100%, 96%, and 100% in healthy controls, respectively (P,0.001). Neutralization against B.1.1.7 was detectable in all kidney transplant recipients with seroconversion, with a median serum dilution that reduces infection of cells by 50% of 80 (interquartile range, 80-320). In contrast, only 23 of 36 (64%) and 24 of 36 (67%) kidney transplant recipients showed neutralization against B.1.351 and B.1.617.2, respectively, with median serum dilutions that reduce infection of cells by 50% of 20 (interquartile range, 0-40) and 20 (interquartile range, 0-40), respectively. Neutralization against different variants was significantly higher in healthy controls (P,0.001), with all patients showing neutralization against all tested variants. Conclusions: seroconverted kidney transplant recipients show impaired neutralization against emerging variants of concern after standard two-dose vaccination., Dietmar Hopp Stiftung; German Federal Research Network Applied Surveillance and Testing; Network University Medicine; fightCOVID@DKFZ Initiative; Helmholtz Association Initiative and Networking Fund Project Virological and Immunological Determinants of COVID-19 Pathogenesis; Lessons to Get Prepared for Future Pandemics; Heidelberg Faculty of Medicine Rahel Goitein-Strauss Program; Heidelberg Faculty of Medicine Physician Scientist Program

Published
2022

4. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

Author

Louise Benning, Christian Morath, Marie Bartenschlager, Marvin Reineke, Maximilian Töllner, Christian Nusshag, Florian Kälble, Paula Reichel, Matthias Schaier, Katrin Klein, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Claudius Speer, Süsal, Caner, Benning, L., Morath, C., Bartenschlager, M., Reineke, M., Töllner, M., Nusshag, C., Kälble, F., Reichel, P., Schaier, M., Klein, K., Schnitzler, P., Zeier, M., Bartenschlager, R., Speer, C., and Koç University Hospital

Subjects
Variants of concern, Microbiology (medical), Delta variant, COVID-19, SARS-CoV-2, Vaccination, Health Personnel, Immunology, General Medicine, Antibodies, Viral, Antibodies, Neutralizing, Infectious Diseases, Neutralization Tests, Immunoglobulin G, Humans, Original Article, Prospective Studies, BNT162 Vaccine
Abstract

Objectives: humoral immunity wanes over time after two-dose BNT162b2 vaccination. Emerging variants of concern, such as the B.1.617.2 (delta) variant, are increasingly responsible for breakthrough infections owing to their higher transmissibility and partial immune escape. Longitudinal data on neutralization against the B.1.617.2 (delta) variant are urgently needed to guide vaccination strategies. Methods: in this prospective longitudinal observational study, anti-S1 IgG and surrogate neutralizing antibodies were measured in 234 collected samples from 60 health care workers after two-dose vaccination with BNT162b2 at five different time points over an 8-month period. In addition, antibodies against various severe acute respiratory syndrome coronavirus 2 epitopes, neutralization against wild-type, and cross-neutralization against the B.1.617.2 (delta) variant using a live virus assay were measured 6 weeks (second time point) and 8 months (last time point) after first vaccine dose. Results: median (interquartile range) anti-S1 IgG, surrogate neutralizing, and receptor-binding domain antibodies decreased significantly from a maximum level of 147 (102–298), 97 (96–98), and 20 159 (19 023–21 628) to 8 (4–13), 92 (80–96), and 15 324 (13 055–17 288) at the 8-month follow-up, respectively (p < 0.001 for all). Neutralization against the B.1.617.2 (delta) variant was detectable in all 36 (100%) participants at 6 weeks and in 50 of 53 (94%) participants 8 months after first vaccine dose. Median (interquartile) ID50 as determined by a live virus assay decreased from 160 (80–320) to 40 (20–40) (p < 0.001). Discussion: although humoral immunity wanes over time after two-dose BNT162b2 vaccination in healthy individuals, most individuals still had detectable neutralizing activity against the B.1.617.2 (delta) variant after 8 months., Dietmar Hopp Stiftung; Heidelberg Faculty of Medicine Rahel Goitein-Strauss Program; Heidelberg Faculty of Medicine Physician Scientist Program; German Federal Research Network Applied Surveillance and Testing (BFAST); Network University Medicine; DKFZ@fightCOVID; Helmholtz Association Initiative and Networking Fund Project Virological and Immunological Determinants of COVID-19 Pathogenesis

Published
2022

5. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

Author

Louise Benning, Katrin Klein, Christian Morath, Marie Bartenschlager, Heeyoung Kim, Mirabel Buylaert, Marvin Reineke, Maximilian Töllner, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Caner Süsal, Ralf Bartenschlager, Matthias Schaier, Claudius Speer, Süsal, Caner, Benning, L., Klein, K., Morath, C., Bartenschlager, M., Kim, H., Buylaert, M., Reineke, M., Töllner, M., Nusshag, C., Kälble, F., Reichel, P., Schnitzler, P., Zeier, M., Bartenschlager, R., Schaier, M., Speer C., and Koç University Hospital

Subjects
COVID-19, Delta variant, SARS-CoV-2, Vaccination, Variants of concern, COVID-19 Vaccines, Renal Dialysis, Immunoglobulin G, Immunology, Immunology and Allergy, Humans, Antibodies, Viral, Antibodies, Neutralizing, BNT162 Vaccine
Abstract

Hemodialysis patients are at high risk for severe COVID-19, and impaired seroconversion rates have been demonstrated after COVID-19 vaccination. Humoral immunity wanes over time and variants of concern with immune escape are posing an increasing threat. Little is known about protection against the B.1.617.2 (delta) variant of concern in hemodialysis patients before and after third vaccination. We determined anti-S1 IgG, surrogate neutralizing, and IgG antibodies against different SARS-CoV-2 epitopes in 84 hemodialysis patients directly before and three weeks after a third vaccine dose with BNT162b2. Third vaccination was performed after a median (IQR) of 119 (109-165) days after second vaccination. In addition, neutralizing activity against the B.1.617.2 (delta) variant was assessed in 31 seroconverted hemodialysis patients before and after third vaccination. Triple seropositivity for anti-S1 IgG, surrogate neutralizing, and anti-RBD antibodies increased from 31/84 (37%) dialysis patients after second to 80/84 (95%) after third vaccination. Neutralizing activity against the B.1.617.2 (delta) variant was significantly higher after third vaccination with a median (IQR) ID50 of 1:320 (1:160-1:1280) compared with 1:20 (0-1:40) before a third vaccine dose (P, Dietmar Hopp Stiftung; Heidelberg Faculty of Medicine Rahel Goitein-Strauss Program

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results